Table 1. FDA Approval & Survival Benefit – Castrate Resistant Prostate Cancer

<table>
<thead>
<tr>
<th>CRPC/ HRPC Drug (generic name)</th>
<th>TYPE OF Drug</th>
<th>MEDIAN OVERALL SURVIVAL Benefit</th>
<th>RISK OF DEATH Reduced by</th>
<th>When Compared To</th>
<th>Previous Taxotere?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taxotere (docetaxel) 2004</td>
<td>Chemotherapy (IV drip)</td>
<td>2.5 mos 24% (7)</td>
<td>mitoxantrone (other chemos)</td>
<td>NO</td>
<td></td>
</tr>
<tr>
<td>Jevtana (cabazitaxel) 2010</td>
<td>Chemotherapy (IV drip)</td>
<td>2.4 mos 30% (4)</td>
<td>mitoxantrone (other chemos)</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>PROVENGE (sipuleucel-T) 2011</td>
<td>Immunotherapy (pheresis + IV drip)</td>
<td>4.1 mos 22.5% (9)</td>
<td>Placebo, then PROVENGE</td>
<td>Some yes, Some NO</td>
<td></td>
</tr>
<tr>
<td>Zytiga (abiraterone) 2012</td>
<td>Secondary hormonal therapy (pills)</td>
<td>3.9 mos 35% (10)</td>
<td>Placebo</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Xtandi (enzalutamide) 2012</td>
<td>Secondary hormonal therapy (pills)</td>
<td>4.8 mos 37% (11)</td>
<td>Placebo</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Xofigo (radium 223) 2013</td>
<td>Injectable radiation for bone (injection)</td>
<td>3.6 mos 30.5% (12)</td>
<td>Placebo</td>
<td>Some yes, Some NO</td>
<td></td>
</tr>
</tbody>
</table>

Since 2010, we have seen several drugs receive FDA approval for men with castrate resistant prostate cancer. Each time a drug is approved, the Median Overall Survival benefit is quoted (see Table 1). This leaves men and their families thinking this is a finite number that applies to them personally and often trying to weigh out the months of promised life against the expensive price tag associated with the new drug. Since these are the 2 numbers that inevitably make the news, this type of “math” is not surprising. However, let me shed more light on more numbers which should help give a broader perspective and change up the mathematics a little.

When a drug is FDA approved, the pharmaceutical companies are highly regulated in what they can print and say. For example, they are not allowed to make claims about their drug that weren’t in the published Product Information (PI) document approved by the FDA. The PI document may quote the Median Overall Survival, but usually doesn’t mention the mean (average) or the range in overall survival from the studies. So MOS is often the only number we’re given, although some companies have found an alternative FDA-approved way to report their data. In Figure 2, Dendreon, the manufacturer of Provenge, illustrates the percentage likelihood of increased survival three years in the future compared to men who were treated with placebo.

Fear of Death
This is a difficult subject to discuss but since I was forced to face it head-on for 13 years with my husband, it is something I’m ready to talk about. Dominic lost his cancer battle in April 2013 – 13 years and 1 month after his diagnosis of widely metastatic prostate cancer. This type of journey brings out every emotion you can name, and magnifies them at times. Some of them are familiar – some of them are a surprise. But the one emotion I had to face most over those 13 years was simply fear. Fear of losing my husband – fear of my son losing his father – and every other fear that goes with it. Sometimes I would retreat to deal with the feelings. Often I would pray. But, I was a busy caretaker, so long car rides to do errands often became my getaway. I did find this one simple truth; facing my fears made me a better advocate for my family. But I had to retreat to do it. Running away from my fears only made me more anxious and fearful. I believe that facing your fears is an important element of patient empowerment and especially advocacy. It makes you stronger, not weaker. Find some time to do this for yourself and the ones you love.

Defying the Odds
The prostate cancer community is full of men who have beaten the odds, defying the statistics.

2013 Prostate Cancer Run Results - Los Angeles
PCRI would like to thank everyone who came out to help raise awareness at Dockweiler State Beach on July 20th! This year, PCRI teamed up with Urologist Specialists of Southern California and ZERO - The End of Prostate Cancer for our second annual Prostate Cancer Run.

The race is part of the Great Prostate Cancer Challenge, America’s Premier Men’s Health Event Series, and taking place in 38 cities nationwide in 2013 with the mission of raising awareness and funds to provide research and free testing. In 2012, the race series attracted more than 18,000 participants and raised more than $2.1 million for advocacy toward prostate cancer research, providing early detection and spreading education and awareness.

Male Podium
1st Alec Borsook
2nd Dan Kuch
3rd Sean Gardner

Female Podium
1st Andrea Young
2nd Olivia May
3rd Lisa Uhrig

Top Survivors
1st Jeff Glasser
2nd Philip Toomey
3rd Jeremiah Crowley